<DOC>
	<DOCNO>NCT00598195</DOCNO>
	<brief_summary>What pharmacokinetics ketamine infant child require ketamine induction anesthesia cardiac surgery require CPB ? Specific Aim 1 : To determine pharmacokinetic parameter single intravenous bolus dose ketamine infant child undergo cardiac surgery without CPB ( cardio-pulmonary bypass ) . Specific Aim 2 : To describe disposition ketamine 's primary active metabolite , norketamine , follow single intravenous bolus dose ketamine infant child undergo cardiac surgery without CPB . Specific Aim 3 : To determine relationship ketamine norketamine pharmacokinetic parameter age well CPB time .</brief_summary>
	<brief_title>Ketamine Pharmacokinetics Children Having Heart Surgery</brief_title>
	<detailed_description>The role ketamine pediatric anesthesia well establish . It one commonly use agent conscious sedation pediatrics . Its widespread use stem abrupt onset action brief duration sedation . There limited ketamine pharmacokinetic data child none knowledge infant young child give intravenous bolus dose surgical procedure include cardiopulmonary bypass . Ketamine market racemic mixture ( 50:50 mixture S- R-ketamine enantiomer ) . Ketamine undergoes N-demethylation ( CYP3B6 , 2C9 , 3A4 ) primary active metabolite , norketamine , minor inactive metabolite , dehydroxynorketamine , generate secondary direct oxidation . Ketamine exhibit high intrinsic clearance hepatic clearance dependent hepatic blood flow normal circumstance . One inherent disadvantage associate use cardiopulmonary bypass ( CPB ) potential organ dysfunction post-operatively . We propose open-label control study describe disposition ketamine 28 infant child undergo cardiac surgery ( n=16 ) without ( n=12 ) CPB . We anticipate cardiopulmonary bypass alters pharmacokinetics ketamine .</detailed_description>
	<mesh_term>Ketamine</mesh_term>
	<criteria>â‰¤ 6 year age cardiac surgical procedure Indwelling arterial line central venous line blood sample patient know hepatic dysfunction ( &gt; 3 time normal AST &amp; ALT ) clinically significant alteration ( determined investigator ) hemoglobin hematocrit patient receive medication know potent inhibitor inducer CYP3A4 CYP2C19 patient significant malnutrition ( &lt; 1 % tile ageadjusted weight ) patient enrolled study require frequent blood sample cardiac surgery contraindication ketamine administration ketamine administration within previous 24 hour Patients known history pulmonary hypertension</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Ketamine</keyword>
	<keyword>Phamacokinetics</keyword>
	<keyword>Cardiopulmonary bypass ( CPB )</keyword>
	<keyword>ketamine/norketamine pharmacokinetic parameter</keyword>
</DOC>